Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters








Database
Language
Publication year range
1.
Genet Epidemiol ; 45(5): 537-548, 2021 07.
Article in English | MEDLINE | ID: mdl-33998042

ABSTRACT

This study sets out to establish the suitability of saliva-based whole-genome sequencing (WGS) through a comparison against blood-based WGS. To fully appraise the observed differences, we developed a novel technique of pseudo-replication. We also investigated the potential of characterizing individual salivary microbiomes from non-human DNA fragments found in saliva. We observed that the majority of discordant genotype calls between blood and saliva fell into known regions of the human genome that are typically sequenced with low confidence; and could be identified by quality control measures. Pseudo-replication demonstrated that the levels of discordance between blood- and saliva-derived WGS data were entirely similar to what one would expect between technical replicates if an individual's blood or saliva had been sequenced twice. Finally, we successfully sequenced salivary microbiomes in parallel to human genomes as demonstrated by a comparison against the Human Microbiome Project.


Subject(s)
Microbiota , Saliva , Genome, Human , Genotype , Humans , Microbiota/genetics , Whole Genome Sequencing
2.
Liver Int ; 35 Suppl 1: 21-6, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25529084

ABSTRACT

The standard of care (SOC) for the treatment of HCV genotype 2 (HCV-2) was pegylated interferon alpha plus ribavirin (PEG-IFN/RBV) at weight-based doses for a response-guided duration. The launches of sofosbuvir and daclatasvir in 2014 have resulted in new, better tolerated and shorter treatment. The combination of sofosbuvir and RBV for 12 weeks appears to be the new SOC in both European and American guidelines. The cost and therefore the access to this treatment remains a problem in many countries because of major economic constraints. For the few more difficult-to-treat patients, a combination of direct acting antivirals may be suitable and is being studied in ongoing trials. Because of rapidly changing treatment recommendations, the decision to treat HCV-2 patients with currently approved drugs or to wait until a better option is available in the future, must be made according to the stage of fibrosis.


Subject(s)
Drug Therapy, Combination/trends , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/epidemiology , Ribavirin/therapeutic use , Uridine Monophosphate/analogs & derivatives , Drug Therapy, Combination/methods , Genotype , Hepacivirus/drug effects , Hepatitis C, Chronic/genetics , Humans , Prevalence , Sofosbuvir , Uridine Monophosphate/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL